The science to cure Parkinson's disease exists, yet new treatments are not prioritised.
This is the opinion of Tom Isaacs, president and co-founder of the Cure Parkinson's Trust, who said that it was a lengthy and bureaucratic process to try and translate research breakthroughs into readily available medicines.
He explained that the existing clinical trial structure was better suited to making small improvements in current treatments, but since they only managed the symptoms of the condition, it will be sometime before a cure is available.
A new report from the Neurological Alliance found that by 2020, the number of people suffering from Parkinson's and Motor Neurone Disease will have increased by more than a quarter due to an aging population.
Mr Isaacs said the solution to the problem was not just to improve the standard of care, but to reduce the need for care by focusing on pioneering new drugs with the potential to cure the conditions.